Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 7/20 | 0.36 |
| ▸ | CTSB | P07858 | 7/20 | 0.36 |
| ▸ | CTSH | P09668 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475722 | 0.90 | — | — | |
| SCHEMBL6344607 | 0.87 | CTSK (0.40) | CTSKCTSLCTSBCTSH | |
| SCHEMBL13723044 | 0.72 | ADH1B (0.43) | CTSKADH1BADH1CADH1AADH4 | |
| SCHEMBL29278682 | 0.72 | CTSK (0.39) | CTSKCTSLCTSBCTSH | |
| SCHEMBL27437240 | 0.72 | CTSK (0.39) | CTSKCTSLCTSBCTSH | |
| SCHEMBL21211687 | 0.70 | KDM4E (0.38) | CTSKCTSLCTSBCTSH | |
| SCHEMBL27534752 | 0.70 | KDM4E (0.38) | CTSKCTSLCTSBCTSH | |
| SCHEMBL2265272 | 0.68 | ADH1B (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4395112 | 0.68 | CTSK (0.37) | CTSKCTSLCTSBCTSH | |
| SCHEMBL3992964 | 0.68 | CTSK (0.40) | CTSKCTSLCTSBCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | ALKBH3, ALKBH2, ALKBH1 | CTSK 804/4885ADH1B 1149/4885ADH1C 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.